Disruption of the nuclear membrane by perinuclear inclusions of mutant huntingtin causes cell-cycle re-entry and striatal cell death in mouse and cell models of Huntington's disease

Human Molecular Genetics

Volumn 24, Issue 6, 2015, Pages 1602-1616

  Liu, Kuan Yu ^a,b   Shyu, Yu Chiau ^a,b   Barbaro, Brett A ^d   Lin, Yuan Ta ^b   Chern, Yijuang ^c   Thompson, Leslie Michels ^e   Shen, Che Kun James ^a,b   Marsh, J Lawrence ^d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B1; CYCLIN DEPENDENT KINASE 5; HUNTINGTIN; MATURATION PROMOTING FACTOR; MUTANT PROTEIN; HTT PROTEIN, HUMAN; NERVE PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE RE ENTRY; CELL DEATH; CELL DISRUPTION; CELL INCLUSION; CELL NUCLEUS INCLUSION BODY; CELL NUCLEUS MEMBRANE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA TRANSFECTION; GENETIC TRANSFECTION; HISTOCHEMISTRY; HUNTINGTON CHOREA; IN VIVO STUDY; MOTOR CONTROL; MOTOR PERFORMANCE; MOUSE; NONHUMAN; NUCLEAR PORE COMPLEX; PRIORITY JOURNAL; PROTEIN LOCALIZATION; ANIMAL; CELL CYCLE; CORPUS STRIATUM; CYTOLOGY; DISEASE MODEL; GENETICS; HUMAN; MUTATION; NERVE CELL; PATHOLOGY; TRANSGENIC MOUSE; ULTRASTRUCTURE;

MUS; MUS MUSCULUS;

ANIMALS; CELL CYCLE; CELL DEATH; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; HUMANS; HUNTINGTON DISEASE; INCLUSION BODIES; MICE; MICE, TRANSGENIC; MUTATION; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR ENVELOPE;

EID: 84936094359     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu574     Document Type: Article

References (70)

1. Perutz, M.F. and Windle, A.H. (2001) Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats. Nature, 412, 143-144.
2. Portera-Cailliau, C., Hedreen, J.C., Price, D.L. and Koliatsos, V.E. (1995) Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J. Neurosci., 15, 3775-3787.
3. Dragunow, M., Faull, R.L., Lawlor, P., Beilharz, E.J., Singleton, K., Walker, E.B. and Mee, E. (1995) In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. Neuroreport, 6, 1053-1057.
4. Bjorkoy, G., Lamark, T., Brech, A., Outzen, H., Perander, M., Overvatn, A., Stenmark, H. and Johansen, T. (2005) p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J. Cell Biol., 171, 603-614.
5. Ross, C.A., Margolis, R.L., Rosenblatt, A., Ranen, N.G., Becher, M.W. and Aylward, E. (1997) Huntington disease and the related disorder, dentatorubral-pallidoluysian atrophy (DRPLA). Medicine (Baltimore), 76, 305-338.
6. Orr, H.T. (2001) Hereditary ataxia. An unfolded protein. Lancet, 358 (Suppl), S35.
7. Li, S.H. and Li, X.J. (2004) Huntingtin and its role in neuronal degeneration. Neuroscientist, 10, 467-475.
8. Mielcarek, M., Landles, C., Weiss, A., Bradaia, A., Seredenina, T., Inuabasi, L., Osborne, G.F., Wadel, K., Touller, C., Butler, R. et al. (2013) HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration. PLoS Biol., 11, e1001717.
9. England, J.L. and Kaganovich, D. (2011) Polyglutamine shows a urea-like affinity for unfolded cytosolic protein. FEBS Lett., 585, 381-384.
10. Kaganovich, D., Kopito, R. and Frydman, J. (2008) Misfolded proteins partition between two distinct quality control compartments. Nature, 454, 1088-1095.
11. Waelter, S., Boeddrich, A., Lurz, R., Scherzinger, E., Lueder, G., Lehrach, H. and Wanker, E.E. (2001) Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol. Biol. Cell, 12, 1393-1407.
12. Arrasate, M., Mitra, S., Schweitzer, E.S., Segal, M.R. and Finkbeiner, S. (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature, 431, 805-810.
13. DiFiglia, M., Sapp, E., Chase, K.O., Davies, S.W., Bates, G.P., Vonsattel, J.P. and Aronin, N. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science, 277, 1990-1993.
14. Gutekunst, C.A., Li, S.H., Yi, H., Mulroy, J.S., Kuemmerle, S., Jones, R., Rye, D., Ferrante, R.J., Hersch, S.M. and Li, X.J. (1999) Nuclear and neuropil aggregates inHuntington's disease: relationship to neuropathology. J. Neurosci., 19, 2522-2534.
15. Goldberg, Y.P., Nicholson, D.W., Rasper, D.M., Kalchman, M. A., Koide, H.B., Graham, R.K., Bromm, M., Kazemi-Esfarjani, P., Thornberry, N.A., Vaillancourt, J.P. et al. (1996) Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nat. Genet., 13, 442-449.
16. Wellington, C.L., Ellerby, L.M., Hackam, A.S., Margolis, R.L., Trifiro, M.A., Singaraja, R., McCutcheon, K., Salvesen, G.S., Propp, S.S., Bromm, M. et al. (1998) Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem., 273, 9158-9167.
17. Lunkes, A., Lindenberg, K.S., Ben-Haiem, L., Weber, C., Devys, D., Landwehrmeyer, G.B., Mandel, J.L. and Trottier, Y. (2002) Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol. Cell, 10, 259-269.
18. Lunkes, A. and Mandel, J.L. (1998) A cellular model that recapitulates major pathogenic steps of Huntington's disease. Hum. Mol. Genet., 7, 1355-1361.
19. Li, H., Li, S.H., Yu, Z.X., Shelbourne, P. and Li, X.J. (2001) Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J. Neurosci., 21, 8473-8481.
20. Sawa, A., Nagata, E., Sutcliffe, S., Dulloor, P., Cascio, M.B., Ozeki, Y., Roy, S., Ross, C.A. and Snyder, S.H. (2005) Huntingtin is cleaved by caspases in the cytoplasm and translocated to the nucleus via perinuclear sites in Huntington's disease patient lymphoblasts. Neurobiol. Dis., 20, 267-274.
21. Sathasivam, K., Neueder, A., Gipson, T.A., Landles, C., Benjamin, A.C., Bondulich, M.K., Smith, D.L., Faull, R.L., Roos, R.A., Howland, D. et al. (2013) Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc. Natl Acad. Sci. USA., 110, 2366-2370.
22. Menalled, L.B. (2005) Knock-in mouse models of Huntington's disease. NeuroRx, 2, 465-470.
23. Kuhn, A., Goldstein, D.R., Hodges, A., Strand, A.D., Sengstag, T., Kooperberg, C., Becanovic, K., Pouladi, M.A., Sathasivam, K., Cha, J.H. et al. (2007) Mutant Huntington's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum. Mol. Genet., 16, 1845-1861.
24. Landles, C., Sathasivam, K., Weiss, A., Woodman, B., Moffitt, H., Finkbeiner, S., Sun, B., Gafni, J., Ellerby, L.M., Trottier, Y. et al. (2010) Proteolysis of mutant Huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J. Biol. Chem., 285, 8808-8823.
25. Seward, M.E., Swanson, E., Norambuena, A., Reimann, A., Cochran, J.N., Li, R., Roberson, E.D. and Bloom, G.S. (2013) Amyloidbeta signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease. J. Cell Sci., 126, 1278-1286.
26. Heintz, N. (1993) Cell death and the cell cycle: a relationship between transformation and neurodegeneration?. Trends Biochem. Sci., 18, 157-159.
27. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S.W. et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 87, 493-506.
28. Menalled, L.B. and Chesselet, M.F. (2002) Mouse models of Huntington's disease. Trends Pharmacol. Sci., 23, 32-39.
29. Lin, Y.T., Chern, Y., Shen, C.K., Wen, H.L., Chang, Y.C., Li, H., Cheng, T.H. and Hsieh-Li, H.M. (2011) Human mesenchymal stem cells prolong survival and ameliorate motor deficit through trophic support in Huntington's disease mouse models. PLoS One, 6, e22924.
30. Morton, A.J., Glynn, D., Leavens, W., Zheng, Z., Faull, R.L., Skepper, J.N. and Wight, J.M. (2009) Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Neurobiol. Dis., 33, 331-341.
31. Mullen, R.J., Buck, C.R. and Smith, A.M. (1992) NeuN, a neuronal specific nuclear protein in vertebrates. Development, 116, 201-211.
32. Gong, B., Lim, M.C., Wanderer, J., Wyttenbach, A. and Morton, A.J. (2008) Time-lapse analysis of aggregate formation in an inducible PC12 cell model of Huntington's disease reveals time-dependent aggregate formation that transiently delays cell death. Brain Res. Bull., 75, 146-157.
33. Kazantsev, A., Walker, H.A., Slepko, N., Bear, J.E., Preisinger, E., Steffan, J.S., Zhu, Y.Z., Gertler, F.B., Housman, D.E., Marsh, J.L. et al. (2002) A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila. Nat. Genet., 30, 367-376.
34. Preisinger, E., Jordan, B.M., Kazantsev, A. and Housman, D. (1999) Evidence for a recruitment and sequestration mechanism in Huntington's disease. Philos. Trans. R. Soc. Lond. B Biol. Sci., 354, 1029-1034.
35. Vincent, I., Jicha, G., Rosado, M. and Dickson, D.W. (1997) Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain. J. Neurosci., 17, 3588-3598.
36. Lopes, J.P., Oliveira, C.R. and Agostinho, P. (2009) Cdk5 acts as a mediator of neuronal cell cycle re-entry triggered by amyloid-beta and prion peptides. Cell Cycle, 8, 97-104.
37. Yoshikawa, K. (2000) Cell cycle regulators in neural stem cells and postmitotic neurons. Neurosci. Res., 37, 1-14.
38. Zhu, X., McShea, A., Harris, P.L., Raina, A.K., Castellani, R.J., Funk, J.O., Shah, S., Atwood, C., Bowen, R., Bowser, R. et al. (2004) Elevated expression of a regulator of the G2/M phase of the cell cycle, neuronal CIP-1-associated regulator of cyclin B, in Alzheimer's disease. J. Neurosci. Res., 75, 698-703.
39. Arendt, T., Rodel, L., Gartner, U. and Holzer, M. (1996) Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimer's disease. Neuroreport, 7, 3047-3049.
40. Slow, E.J., van Raamsdonk, J., Rogers, D., Coleman, S.H., Graham, R.K., Deng, Y., Oh, R., Bissada, N., Hossain, S.M., Yang, Y.Z. et al. (2003) Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet., 12, 1555-1567.
41. Schilling, G., Becher, M.W., Sharp, A.H., Jinnah, H.A., Duan, K., Kotzuk, J.A., Slunt, H.H., Ratovitski, T., Cooper, J.K., Jenkins, N. A. et al. (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet., 8, 397-407.
42. Seredenina, T. and Luthi-Carter, R. (2012) What have we learned from gene expression profiles in Huntington's disease?. Neurobiol. Dis., 45, 83-98.
43. Ross, C.A. and Tabrizi, S.J. (2011) Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol., 10, 83-98.
44. Zuchner, T. and Brundin, P. (2008) Mutant huntingtin can paradoxically protect neurons from death. Cell Death Differ., 15, 435-442.
45. Stack, E.C., Kubilus, J.K., Smith, K., Cormier, K., Del Signore, S. J., Guelin, E., Ryu, H., Hersch, S.M. and Ferrante, R.J. (2005) Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J. Comp. Neurol., 490, 354-370.
46. Beilharz, E.J., Williams, C.E., Dragunow, M., Sirimanne, E.S. and Gluckman, P.D. (1995) Mechanisms of delayed cell death following hypoxic-ischemic injury in the immature rat: evidence for apoptosis during selective neuronal loss. Brain Res. Mol. Brain Res., 29, 1-14.
47. Turmaine, M., Raza, A., Mahal, A., Mangiarini, L., Bates, G.P. and Davies, S.W. (2000) Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA., 97, 8093-8097.
48. Kazemi-Esfarjani, P. and Benzer, S. (2000) Genetic suppression of polyglutamine toxicity in Drosophila. Science, 287, 1837-1840.
49. Chang, D.T., Rintoul, G.L., Pandipati, S. and Reynolds, I.J. (2006) Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiol. Dis., 22, 388-400.
50. Yamamoto, A., Lucas, J.J. and Hen, R. (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell, 101, 57-66.
51. Davies, S.W., Turmaine, M., Cozens, B.A., DiFiglia, M., Sharp, A.H., Ross, C.A., Scherzinger, E., Wanker, E.E., Mangiarini, L. and Bates, G.P. (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell, 90, 537-548.
52. Ossato, G., Digman, M.A., Aiken, C., Lukacsovich, T., Marsh, J.L. and Gratton, E. (2010) A two-step path to inclusion formation of huntingtin peptides revealed by number and brightness analysis. Biophys. J., 98, 3078-3085.
53. Cooper, J.K., Schilling, G., Peters, M.F., Herring, W.J., Sharp, A.H., Kaminsky, Z., Masone, J., Khan, F.A., Delanoy, M., Borchelt, D.R. et al. (1998) Truncated N-terminal fragments of huntingtin with expanded glutamine repeats formnuclear and cytoplasmic aggregates in cell culture. Hum. Mol. Genet., 7, 783-790.
54. Moffitt, H., McPhail, G.D., Woodman, B., Hobbs, C. and Bates, G.P. (2009) Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease. PLoS One, 4, e8025.
55. Orth, M., Cooper, J.M., Bates, G.P. and Schapira, A.H. (2003) Inclusion formation in Huntington's disease R6/2 mouse muscle cultures. J. Neurochem., 87, 1-6.
56. Suhr, S.T., Senut, M.C., Whitelegge, J.P., Faull, K.F., Cuizon, D. B. and Gage, F.H. (2001) Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression. J. Cell Biol., 153, 283-294.
57. Hamirally, S., Kamil, J.P., Ndassa-Colday, Y.M., Lin, A.J., Jahng, W.J., Baek, M.C., Noton, S., Silva, L.A., Simpson-Holley, M., Knipe, D.M. et al. (2009) Viral mimicry of Cdc2/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress. PLoS Pathog., 5, e1000275.
58. Benn, C.L., Landles, C., Li, H., Strand, A.D., Woodman, B., Sathasivam, K., Li, S.H., Ghazi-Noori, S., Hockly, E., Faruque, S.M. et al. (2005) Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease. Hum. Mol. Genet., 14, 3065-3078.
59. Martin-Aparicio, E., Avila, J. and Lucas, J.J. (2002) Nuclear localization of N-terminal mutant huntingtin is cell cycle dependent. Eur. J. Neurosci., 16, 355-359.
60. Pelegri, C., Duran-Vilaregut, J., del Valle, J., Crespo-Biel, N., Ferrer, I., Pallas, M., Camins, A. and Vilaplana, J. (2008) Cell cycle activation in striatal neurons from Huntington's disease patients and rats treated with 3-nitropropionic acid. Int. J. Dev. Neurosci., 26, 665-671.
61. Lee, H.G., Casadesus, G., Zhu, X., Castellani, R.J., McShea, A., Perry, G., Petersen, R.B., Bajic, V. and Smith, M.A. (2009) Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease. Neurochem. Int., 54, 84-88.
62. Wu, Q., Combs, C., Cannady, S.B., Geldmacher, D.S. and Herrup, K. (2000) Beta-amyloid activated microglia induce cell cycling and cell death in cultured cortical neurons. Neurobiol. Aging, 21, 797-806.
63. McShea, A., Lee, H.G., Petersen, R.B., Casadesus, G., Vincent, I., Linford, N.J., Funk, J.O., Shapiro, R.A. and Smith, M.A. (2007) Neuronal cell cycle re-entry mediates Alzheimer disease-type changes. Biochim. Biophys. Acta, 1772, 467-472.
64. Yang, Y., Varvel, N.H., Lamb, B.T. and Herrup, K. (2006) Ectopic cell cycle events link human Alzheimer's disease and amyloid precursor protein transgenic mouse models. J. Neurosci., 26, 775-784.
65. Khurana, V. and Feany, M.B. (2007) Connecting cell-cycle activation to neurodegeneration in Drosophila. Biochim. Biophys. Acta, 1772, 446-456.
66. Klein, J.A. and Ackerman, S.L. (2003) Oxidative stress, cell cycle, and neurodegeneration. J. Clin. Invest., 111, 785-793.
67. Lopes, J.P. and Agostinho, P. (2011) Cdk5: multitasking between physiological and pathological conditions. Prog. Neurobiol., 94, 49-63.
68. Patrick, G.N., Zukerberg, L., Nikolic, M., de la Monte, S., Dikkes, P. and Tsai, L.H. (1999) Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature, 402, 615-622.
69. Li, X.J. and Li, S. (2012) Influence of species differences on the neuropathology of transgenic Huntington's disease animal models. J. Genet. Genomics, 39, 239-245.
70. Trushina, E., Dyer, R.B., Badger, J.D. 2nd, Ure, D., Eide, L., Tran, D.D., Vrieze, B.T., Legendre-Guillemin, V., McPherson, P.S., Mandavilli, B.S. et al. (2004) Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol. Cell. Biol., 24, 8195-8209.